# Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

> **NCT01934127** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 427 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Investigational H7N1 vaccine GSK2789869A
- **BIOLOGICAL:** Investigational H7N1 vaccine GSK2789868A
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01934127
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-26
- **Primary completion:** 2013-11-01
- **Final completion:** 2014-10-20
- **Target enrollment:** 427 (ACTUAL)
- **Last updated:** 2017-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01934127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01934127, "Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01934127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*